INSTITUT CURIE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1909-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.curie.fr
Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- Drug: 68Ga-FAPI-46 for PET / CT scan and 177Lu-EB-FAPI for therapy
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 35
- Registration Number
- NCT06659705
- Locations
- 🇫🇷
Institut Curie -site Saint-Cloud, Saint-cloud, France
Comparative Evaluation of Care Strategies on Dressing Change-induced Bleeding in Patients With Bleeding Malignant Wounds
Not Applicable
Recruiting
- Conditions
- Malignant Wound
- Interventions
- Other: Algosteril
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 108
- Registration Number
- NCT06581809
- Locations
- 🇫🇷
EHPAD Laurent Antoine, Agde, France
🇫🇷Hôpital Saint-Loup, Agde, France
🇫🇷Centre François Baclesse, Caen, France
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid
Not Applicable
Recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Procedure: Biopsy
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 110
- Registration Number
- NCT06459791
- Locations
- 🇫🇷
Institut Curie, Saint-Cloud, France
🇫🇷Hôpital Saint-Louis - AP-HP Senopole, Paris, France
Optimizing Bronchopulmonary Cancer Screening
Not Applicable
Recruiting
- Conditions
- Diagnoses DiseaseBronchopulmonary Disease
- Interventions
- Other: ScreeningOther: InclusionOther: Chest CTscan and follow-up
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 500
- Registration Number
- NCT06439901
- Locations
- 🇫🇷
Centre CTPS Bobigny Bondy, Bobigny, France
🇫🇷Centre Municipal de Santé Simone Veil, Issy-les-Moulineaux, France
🇫🇷Centre Municipal de Santé Jacqueline Akoun-Cornet, Malakoff, France
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
Not Applicable
Recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Procedure: 68Ga-FAPI-46 PET/CT imaging
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 60
- Registration Number
- NCT06349512
- Locations
- 🇫🇷
Hôpital Privé d'Antony, Antony, France
🇫🇷Institut Curie -site Paris, Paris, France
🇫🇷GH Diaconesses Croix Saint-Simon, Paris, France
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: PLX038 + Tuvusertib
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 92
- Registration Number
- NCT06337630
- Locations
- 🇫🇷
Institut Curie, Saint-Cloud, France
Early Detection of Triple Negative Breast Cancer Relapse
Not Applicable
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Diagnostic Test: ctDNA monitoringDiagnostic Test: 68Ga-FAPI-46-PET-CT
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 450
- Registration Number
- NCT06225505
- Locations
- 🇫🇷
Sainte-Catherine Institut du Caner Avignon-Provence, Avignon, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Phase 3
Recruiting
- Conditions
- Breast Carcinoma
- Interventions
- Combination Product: Endocrine therapyCombination Product: Endocrine therapy combined with the local treatment of FES-negative lesionsCombination Product: Chemotherapy
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 300
- Registration Number
- NCT06195709
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Francois Baclesse, Caen, France
🇫🇷Centre Georges Francois Leclerc, Dijon, France
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Radiation: 68Ga-FAPI-46 PET/CTBiological: Tumor samples analysis
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 130
- Registration Number
- NCT06175390
- Locations
- 🇫🇷
Institut Curie, Saint-Cloud, France
A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 44
- Registration Number
- NCT06162351
- Locations
- 🇫🇷
Institut Curie, Saint Cloud, France